Comparison between next-generation sequencing and multiplex polymerase chain reaction assays for nonsmall-cell lung cancer molecular diagnosis.

Publisher: John Wiley & Sons Ltd Country of Publication: United States NLM ID: 101595310 Publication Model: Print Cited Medium: Internet ISSN: 2045-7634 (Electronic) Linking ISSN: 20457634 NLM ISO Abbreviation: Cancer Med Subsets: MEDLINE

Original Publication: [Malden, MA] : John Wiley & Sons Ltd., c2012-

Lung Neoplasms*/diagnosis ; Lung Neoplasms*/genetics ; Lung Neoplasms*/drug therapy ; Carcinoma, Non-Small-Cell Lung*/diagnosis ; Carcinoma, Non-Small-Cell Lung*/genetics ; Carcinoma, Non-Small-Cell Lung*/drug therapy; Humans ; Multiplex Polymerase Chain Reaction ; Mutation ; High-Throughput Nucleotide Sequencing/methods ; Biomarkers

Purpose: Genetic mutation detection has become an important step in nonsmall-cell lung cancer (NSCLC) treatment because of the increasing number of drugs that target genomic rearrangements. A multiplex test that can detect multiple gene mutations prior to treatment is thus necessary. Currently, either next-generation sequencing (NGS)-based or polymerase chain reaction (PCR)-based tests are used. We evaluated the performance of the Oncomine Dx Target Test (ODxTT), an NGS-based multiplex biomarker panel test, and the AmoyDx Pan Lung Cancer PCR Panel (AmoyDx PLC panel), a real-time PCR-based multiplex biomarker panel test.
Materials and Methods: Patients with histologically diagnosed NSCLC and a sufficient sample volume to simultaneously perform the AmoyDx PLC panel and ODxTT-M were included in the study. The success and detection rates of both tests were evaluated.
Results: Biopsies revealed 116 cases of malignancies, 100 of which were NSCLC. Of these, 59 met the inclusion criteria and were eligible for analysis. The success rates were 100% and 98% for AmoyDx PLC panel and ODxTT-M, respectively. Nine driver mutations were detected in 35.9% and 37.3% of AmoyDx PLC and ODxTT-M panels, respectively. EGFR mutations were detected in 14% and 12% of samples using the AmoyDx PLC panel and ODxTT-M, respectively. Of the 58 cases in which both NGS and AmoyDx PLC panels were successful, discordant results were observed in seven cases. These differences were mainly due to different sensitivities of the detection methods used and the gene variants targeted in each test.
Discussion: The AmoyDx PLC panel, a PCR-based multiplex diagnostic test, exhibits a high success rate. The frequency of the nine genes targeted for treatment detected by the AmoyDx PLC panel was comparable to the frequency of mutations detected by ODxTT-M. Clinicians should understand and use the AmoyDx PLC panel and ODxTT-M with respect to their respective performances and limitations.
(© 2024 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.)

PLoS One. 2013 Jun 06;8(6):e62692. (PMID: 23762227)
J Thorac Oncol. 2021 Dec;16(12):2133-2138. (PMID: 34419686)
Thorac Cancer. 2022 Nov;13(22):3217-3224. (PMID: 36203199)
Sci Rep. 2022 Feb 17;12(1):2699. (PMID: 35177674)
Nature. 2018 Jan 24;553(7689):446-454. (PMID: 29364287)
Thorac Cancer. 2020 Aug;11(8):2262-2269. (PMID: 32578376)
Pathol Int. 2020 Dec;70(12):921-931. (PMID: 32956529)
Cancer Sci. 2022 Jan;113(1):221-228. (PMID: 34704312)
Thorac Cancer. 2021 Jan;12(2):194-200. (PMID: 33185331)
JAMA. 2014 May 21;311(19):1998-2006. (PMID: 24846037)
Front Oncol. 2022 Feb 11;12:843299. (PMID: 35223527)
Diagnostics (Basel). 2021 Feb 25;11(3):. (PMID: 33668993)
J Thorac Oncol. 2015 Sep;10(9):1243-1260. (PMID: 26291008)
Cancer Sci. 2019 Apr;110(4):1480-1490. (PMID: 30742731)
Cancer Med. 2024 Apr;13(7):e7162. (PMID: 38572952)
PLoS One. 2016 Mar 03;11(3):e0150528. (PMID: 26937682)
Lung Cancer. 2023 May;179:107190. (PMID: 37058787)

Riken Genesis Co., Ltd.

Keywords: AmoyDx pan lung cancer PCR panel; Oncomine Dx Target Test; nonsmall‐cell lung cancer

0 (Biomarkers)

Date Created: 20240404 Date Completed: 20240405 Latest Revision: 20240406

20240406

PMC10993699

10.1002/cam4.7162

38572952